Shopping Cart
- Remove All
Your shopping cart is currently empty
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $34 | In Stock | |
| 5 mg | $60 | In Stock | |
| 10 mg | $106 | In Stock | |
| 25 mg | $192 | In Stock | |
| 50 mg | $297 | In Stock | |
| 100 mg | $463 | In Stock | |
| 200 mg | $678 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $67 | In Stock |
| Description | Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3. |
| Targets&IC50 | JAK2:5.0 nM, JAK1:3.9 nM, TYK2:4.8 nM, JAK3:0.7 nM |
| In vitro | ASP015K suppresses the IL-2-induced proliferation of human T cells with greater potency than EPO-induced proliferation of human erythroleukemia cells. In human whole blood, ASP015K inhibits STAT5 phosphorylation (pSTAT5). [1] |
| In vivo | In the rat AIA model, ASP015K (p.o.) significantly decreases paw swelling and ankle bone destruction score. [1] |
| Synonyms | JNJ-54781532, ASP015K |
| Molecular Weight | 326.39 |
| Formula | C18H22N4O2 |
| Cas No. | 944118-01-8 |
| Smiles | [H][C@]12CC3C[C@]([H])(CC(O)(C3)C1)C2Nc1c(cnc2[nH]ccc12)C(N)=O |
| Relative Density. | no data available |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: <1 mg/mL Ethanol: <1 mg/mL DMSO: 60 mg/mL (183.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.